Cargando…

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

Despite intensive multimodal therapy, the survival rate for high risk neuroblastoma (HR-NB) remains <50%. Most cases initially respond to treatment but almost half will subsequently relapse with aggressive treatment resistant disease. Novel treatments exploiting the molecular pathology of NB and/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Southgate, Harriet E. D., Chen, Lindi, Curtin, Nicola J., Tweddle, Deborah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145987/ https://www.ncbi.nlm.nih.gov/pubmed/32309213 http://dx.doi.org/10.3389/fonc.2020.00371

Ejemplares similares

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
por: Chen, Lindi, et al.
Publicado: (2012)

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells
por: King, David, et al.
Publicado: (2021)

Targeting the DNA damage response for cancer therapy
por: Curtin, Nicola J.
Publicado: (2023)

Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
por: Trinidad, Eva María, et al.
Publicado: (2023)

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse
por: Chen, Lindi, et al.
Publicado: (2016)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma
por: Herd, Fiona, et al.
Publicado: (2019)

A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma
por: Cimmino, Flora, et al.
Publicado: (2020)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy
por: Czajkowski, Daniel, et al.
Publicado: (2022)

Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma
por: Yu, Eun Young, et al.
Publicado: (2019)

Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
por: Wong, Oscar G. W., et al.
Publicado: (2021)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma
por: Li, Chao, et al.
Publicado: (2022)

Medulloblastoma and the DNA Damage Response
por: McSwain, Leon F., et al.
Publicado: (2022)

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
por: Bukhari, Amirali B., et al.
Publicado: (2022)

Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy
por: Valvo, Victoria, et al.
Publicado: (2023)

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
por: George, Sally L, et al.
Publicado: (2020)

The DNA damage response in mammalian oocytes
por: Carroll, John, et al.
Publicado: (2013)

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases
por: Turchi, John J., et al.
Publicado: (2022)

Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
por: Zhang, Dongdong, et al.
Publicado: (2021)

The cyclin dependent kinase inhibitor p21(Cip1/Waf1) is a therapeutic target in high-risk neuroblastoma
por: Sorteberg, Agnes Luise, et al.
Publicado: (2022)

CRL Ubiquitin Ligases and DNA Damage Response
por: Li, Ju-Mei, et al.
Publicado: (2012)

BRCA1 in the DNA damage response and at telomeres
por: Rosen, Eliot M.
Publicado: (2013)

Regulation of the DNA damage response by ubiquitin conjugation
por: Brinkmann, Kerstin, et al.
Publicado: (2015)

Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond
por: Orth, Michael, et al.
Publicado: (2021)

Pharmacological targets for the induction of ferroptosis: Focus on Neuroblastoma and Glioblastoma
por: Ferrada, Luciano, et al.
Publicado: (2022)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets
por: van Vugt, Marcel A. T. M., et al.
Publicado: (2015)

Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response
por: Das, Shaoli, et al.
Publicado: (2019)

Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma
por: Lei, Huimin, et al.
Publicado: (2022)

Chromatin modifications and the DNA damage response to ionizing radiation
por: Kumar, Rakesh, et al.
Publicado: (2013)

Editorial: Grappling with the Multifaceted World of the DNA Damage Response
por: Porro, Antonio
Publicado: (2016)

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies
por: Tse, Ka Yu, et al.
Publicado: (2022)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics
por: Ambros, Inge M., et al.
Publicado: (2014)

Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy
por: Chan Wah Hak, Charleen M. L., et al.
Publicado: (2022)

Olfactory neuroblastoma: diagnosis, management, and current treatment options
por: Tosoni, Alicia, et al.
Publicado: (2023)

Histone Ubiquitination and Deubiquitination in Transcription, DNA Damage Response, and Cancer
por: Cao, Jian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t97mfduumqltj8097bbdrm5k3e